Xenon Pharmaceuticals XENE Deferred Tax Assets
Deferred Tax Assets at other companies
Other financials
Where this comes from
Reported directly by Xenon Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:DeferredIncomeTaxAssetsNet.
The official record: Xenon Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Xenon Pharmaceuticals's deferred tax assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Xenon Pharmaceuticals's deferred tax assets?
- Xenon Pharmaceuticals (XENE) reported deferred tax assets of $12.42M in Q1 2026.
- How has Xenon Pharmaceuticals's deferred tax assets changed year-over-year?
- Xenon Pharmaceuticals's deferred tax assets increased by 14.1% year-over-year, from $10.88M to $12.42M.
- What is the long-term trend for Xenon Pharmaceuticals's deferred tax assets?
- Over 5 years (2020 to 2025), Xenon Pharmaceuticals's deferred tax assets has grown at a 89.7% compound annual growth rate (CAGR), from $523K to $12.86M.
- What does deferred tax assets mean?
- Represents future tax benefits arising from temporary differences between the book value of assets/liabilities and their tax basis, or from carry-forward tax losses. These assets are realized when the firm generates sufficient taxable income to offset these differences. It serves as an indicator of future tax savings potential.